Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liaoning Chengda Biotechnology Co has a current ratio of 28.42. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Liaoning Chengda Biotechnology Co's Current Ratio or its related term are showing as below:
SHSE:688739'
s Current Ratio Range Over the Past 10 Years
Min: 11.69 Med: 21.16 Max: 38.82
Current: 28.42
During the past 13 years, Liaoning Chengda Biotechnology Co's highest Current Ratio was 38.82. The lowest was 11.69. And the median was 21.16.
SHSE:688739's Current Ratio is ranked better than 95.96% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:688739: 28.42
Liaoning Chengda Biotechnology Co (SHSE:688739) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Liaoning Chengda Biotechnology Co Current Ratio Related Terms
Liaoning Chengda Biotechnology Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liaoning Chengda Biotechnology Co Current Ratio Chart
SHSE:688739 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Liaoning Chengda Biotechnology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liaoning Chengda Biotechnology Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liaoning Chengda Biotechnology Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Liaoning Chengda Biotechnology Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liaoning Chengda Biotechnology Co (SHSE:688739) has a Current Ratio of 28.42 as of Mar. 2026. This is 34% above median its historical median of 21.16. Over the past decade, Liaoning Chengda Biotechnology Co's Current Ratio has ranged from 11.69 to 38.82. According to the industry distribution chart, Liaoning Chengda Biotechnology Co ranks #57 out of 1411 companies in the Biotechnology industry, placing it in the top 4%.
Is Liaoning Chengda Biotechnology Co's Current Ratio too high?
Liaoning Chengda Biotechnology Co's current Current Ratio of 28.42 is 34% above median its 10-year median of 21.16. Over the past 10 years, this metric has ranged from a low of 11.69 to a high of 38.82. The Biotechnology industry median Current Ratio is 3.88. Liaoning Chengda Biotechnology Co's value of 28.42 is 632.5% above this industry median. Based on the distribution chart, Liaoning Chengda Biotechnology Co ranks #57 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liaoning Chengda Biotechnology Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Liaoning Chengda Biotechnology Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Liaoning Chengda Biotechnology Co ranks #57 out of 1411 companies for Current Ratio. This places Liaoning Chengda Biotechnology Co in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Liaoning Chengda Biotechnology Co's value of 28.42 is 632.5% above this benchmark. Historically, Liaoning Chengda Biotechnology Co's own Current Ratio has ranged from 11.69 to 38.82 over the past decade. While the company's 10-year median is 21.16 vs. the industry median of 3.88, Liaoning Chengda Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liaoning Chengda Biotechnology Co's current Current Ratio of 28.42 is 632.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liaoning Chengda Biotechnology Co's current Current Ratio is 28.42, which is 34% above median its own 10-year median of 21.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liaoning Chengda Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co (SHSE:688739) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥22.10, compared to a current price of ¥19.98 — trading 9.6% below its estimated fair value. The current Current Ratio is 28.42, which is 34% above median its 10-year median of 21.16 and 632.5% above the Biotechnology industry median of 3.88. Liaoning Chengda Biotechnology Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Liaoning Chengda Biotechnology Co (SHSE:688739), the current Current Ratio is 28.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liaoning Chengda Biotechnology Co (SHSE:688739) Overvalued in 2026?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co stock appears to be undervalued.
The current stock price of ¥19.98 is trading 9.6% below its estimated GF Value™ of ¥22.10.
GuruFocus considers Liaoning Chengda Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688739:
Current Ratio: 28.42 (34% above median its 10-year median of 21.16)
GF Value™: ¥22.10 vs. price of ¥19.98 (9.6% below fair value)
Industry Position: 632.5% above the Biotechnology median (#57 of 1411)
No single metric tells the full story. See the SHSE:688739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liaoning Chengda Biotechnology Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688739 has been successfully added to your 
